{
  "event_id": "d19771e3ae3c",
  "ticker": "SNY",
  "company_name": "Sanofi",
  "drug_name": "SARCLISA",
  "pdufa_date": "20210331",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:ICARIA-MM Phase 3 (2020)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.519416",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Multiple myeloma",
    "source": "websearch:ICARIA-MM Phase 3 (2020)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.519418",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "isatuximab",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:43:48.137725",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.090759",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:43:48.137725",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:ICARIA-MM Phase 3 (2020)",
    "confidence": 0.95,
    "evidence": [
      "ICARIA-MM Phase 3 (2020)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.519402",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "0.0010",
    "source": "websearch:ICARIA-MM Phase 3 (2020)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.519410",
    "error": null
  },
  "p_value_numeric": 0.001,
  "effect_size": {
    "status": "found",
    "value": "HR 0.596 (40% PFS reduction); mPFS 11.53 vs 6.47 mo",
    "source": "websearch:ICARIA-MM Phase 3 (2020)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:13:40.519413",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma",
    "Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines"
  ],
  "nct_ids": [
    "NCT02990338",
    "NCT03275285"
  ],
  "enrollment": {
    "count": 307,
    "type": "ACTUAL",
    "nct_id": "NCT02990338",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:30:40.349788"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": false,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:21:45.430206",
  "enriched_at": "2026-01-11T20:17:42.785803",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "905a66c27ec5",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "CD38 inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -1746,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.142164",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:26.597868"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:26.597875"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:30.306432",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Sanofi’s multiple myeloma candidate granted FDA orphan drug ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:31.305995",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Press Release: Sarclisa accepted for FDA priority review for ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:32.475878",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:38.487092",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [
      "Sanofi moves on J&J in first-line myeloma with FDA nod Press Release: Sarclisa approved in the US as"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:17:42.785792",
    "search_status": "FOUND"
  }
}